<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621657</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0789</org_study_id>
    <secondary_id>A534265</secondary_id>
    <secondary_id>SMPH/MEDICINE/INFECT DIS</secondary_id>
    <secondary_id>1R03HS025257-01</secondary_id>
    <nct_id>NCT03621657</nct_id>
  </id_info>
  <brief_title>The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation</brief_title>
  <acronym>GRAFT</acronym>
  <official_title>A Phase II Randomized, Double-blind Placebo-controlled Trial to Determine if Fecal Microbiota Transplantation is Efficacious for Hospitalized Patients With C. Difficile Infection History During Antibiotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the gut microbiota and clinical outcomes of&#xD;
      oral FMT during antibiotic treatment, immediately following antibiotic treatment, and&#xD;
      placebo. The second objective is to assess the safety and feasibility of daily oral Fecal&#xD;
      Microbiome Transplant (FMT) as a treatment option.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clostridium difficile is the most frequent bacterial cause of antibiotic-associated diarrhea.&#xD;
      Those with a previous C. difficile infection (CDI) are at high risk of recurrent infection.&#xD;
      Recurrent CDI often occurs when the normal gut microbiota are disrupted. Dysbiosis of the gut&#xD;
      microbiota predisposes to CDI which, despite treatment can recur in 30% of patients. A novel&#xD;
      way to prevent CDI recurrence is by instilling feces from a healthy individual into the&#xD;
      intestine of the CDI patient, thereby restoring balance in the gut microbiota. However, it is&#xD;
      unknown whether or not fecal microbiota transplantation (FMT) is an efficacious choice for&#xD;
      CDI recurrence prevention when used concurrently with antibiotics. We propose a pilot&#xD;
      randomized, double-blind placebo controlled trial comparing oral FMT with placebo in patients&#xD;
      with a history of CDI, currently undergoing antibiotic treatment. We will collect fecal&#xD;
      samples from subjects prior to, during, and after FMT and collect metagenomics and&#xD;
      microbiologic data on microbiota composition and function, and CDI recurrence. The trial's&#xD;
      primary outcome is gut microbial composition and function. Secondary outcomes are feasibility&#xD;
      and safety, and recurrent CDI during the trial period. In this 3 group study, FMT will be&#xD;
      administered daily via oral capsules containing frozen fecal microbiota from universal donors&#xD;
      in group 1, administered at the end of antibiotic treatment for group 2, and group 3 will&#xD;
      receive daily placebo. The results of this study will provide the necessary pilot data to&#xD;
      examine whether or not concurrent FMT in antibiotic treated patients who are at high risk for&#xD;
      recurrent CDI can maintain a diverse healthy GI microbiota.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Actual">February 27, 2020</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase 2, double-blind, randomized, placebo-controlled trial assessing the effects of either daily (group 1) or one-time (group 2) oral FMT on the composition and function of gut microbiome compared to placebo (group 3) in a population of patients with a history of Clostridium difficile infection (CDI).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Efficacy of Oral FMT on Composition and Function of the Gut Microbiota Compared to Placebo.</measure>
    <time_frame>60 days</time_frame>
    <description>Assess microbial composition of stool using 16s targeted sequencing and shotgun metagenomics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Treatment-related Adverse Events in the Oral FMT Regimens Versus Placebo.</measure>
    <time_frame>60 days</time_frame>
    <description>Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0, including serious adverse events, will be assessed. We will also assess proportion of newly diagnosed infectious diseases, which are considered adverse events of special interest (AESI) after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Rate of Clostridium Difficile Infection (CDI) During Oral FMT Regimens Versus Placebo</measure>
    <time_frame>60 days</time_frame>
    <description>Collection of CDI infection rates from baseline to end of study and comparison between both oral FMT groups versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Time to Clostridium Difficile Infection (CDI) and/or Colonization With C. Difficile.</measure>
    <time_frame>60 days</time_frame>
    <description>C. difficile colonization will be detected in stool samples submitted at baseline through end of study. If patients' become colonized, time from randomization to colonization is collected. Comparisons are made between the oral FMT groups and placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>C.Difficile Diarrhea</condition>
  <condition>CDI</condition>
  <arm_group>
    <arm_group_label>Low dose FMT Capsule DE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose FMT Capsule DE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose FMT Capsule DE</intervention_name>
    <description>5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
    <arm_group_label>Low dose FMT Capsule DE</arm_group_label>
    <other_name>FMT Capsule DE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single Dose FMT Capsule DE</intervention_name>
    <description>30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
    <arm_group_label>Single dose FMT Capsule DE</arm_group_label>
    <other_name>FMT Capsule DE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cognitively intact and willing to provide informed consent&#xD;
&#xD;
          2. Willing and able to comply with all study procedures for the duration of the study&#xD;
&#xD;
          3. Able to take oral medications&#xD;
&#xD;
          4. Age 18 or over&#xD;
&#xD;
          5. Recent CDI episode occurring in the last 180 days with completion of therapy as&#xD;
             confirmed by the electronic medical record (EMR)&#xD;
&#xD;
          6. Receiving antibiotics at enrollment for reasons other than CDI and having taken the&#xD;
             antibiotics for no longer than 10 days.&#xD;
&#xD;
          7. Women of childbearing potential in a sexual relationship with men must use an&#xD;
             acceptable method of contraception (including, but not limited to, barriers with&#xD;
             additional spermicidal foam or jelly, intrauterine devices, hormonal contraception&#xD;
             started at least 30 days before enrollment into the study, or intercourse with men who&#xD;
             underwent a vasectomy) for 4 weeks following completion of the study treatment,&#xD;
&#xD;
          8. Males must agree to avoid impregnation of women during and for 4 weeks following&#xD;
             completion of the study treatment.&#xD;
&#xD;
          9. Able to take the test capsule successfully with no signs or symptoms of dysphagia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, lactating, or planning to become pregnant during the study.&#xD;
             Female patients of childbearing potential will take a pregnancy test at the&#xD;
             intervention visit and will be excluded if pregnant.&#xD;
&#xD;
          2. Inability (e.g. dysphagia) to or unwilling to swallow capsules&#xD;
&#xD;
          3. Known or suspected toxic megacolon and or known small bowel ileus&#xD;
&#xD;
          4. Bowel obstruction or other gut motility issues occurring in the last two weeks taht&#xD;
             are unresolved as noted by the patient or in the EMR&#xD;
&#xD;
          5. Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months&#xD;
             before enrollment not including appendectomy or cholecystectomy.&#xD;
&#xD;
          6. History of bariatric or colectomy surgery&#xD;
&#xD;
          7. Concurrent intensive induction chemotherapy, radiation therapy, or biologic treatment&#xD;
             for an active malignancy. Patients on maintenance chemotherapy may be enrolled after&#xD;
             consultation with the medical monitor.&#xD;
&#xD;
          8. Expected life expectancy less than 6 months.&#xD;
&#xD;
          9. Patients with severe anaphylactic or anaphylactoid food allergy.&#xD;
&#xD;
         10. Solid organ transplant recipients ≤90 days post-transplant or on active treatment for&#xD;
             rejection&#xD;
&#xD;
         11. Neutropenia (≤500 neutrophils/mL) or other severe immunosuppression. Anti-tumor&#xD;
             necrosis factor (TNF) will be permitted. Patients on monoclonal antibodies to B and T&#xD;
             cells, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine,&#xD;
             methotrexate), calcineurin inhibitors (tacrolimus, cyclosporine), and mycophenolate&#xD;
             mofetil may only be enrolled after consultation with the medical monitor.&#xD;
&#xD;
         12. At risk of CMV/EBV associated disease, negative immunoglobulin gamma (IgG) testing for&#xD;
             cytomegalovirus (CMV) or Epstein Barr Virus (EBV)&#xD;
&#xD;
         13. Any other gastrointestinal illness including diarrhea&#xD;
&#xD;
         14. On oral vancomycin or metronidazole&#xD;
&#xD;
         15. Having been taking the currently prescribed antibiotic for over 10 days&#xD;
&#xD;
         16. Any condition that would jeopardize the safety or rights of the patient, would make it&#xD;
             unlikely for the patient to complete the study, or would confound the results of the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasia Safdar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <results_first_submitted>February 19, 2021</results_first_submitted>
  <results_first_submitted_qc>February 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FMT</keyword>
  <keyword>Fecal Microbiota Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03621657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose FMT Capsule DE</title>
          <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Oral Capsule</title>
          <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
        </group>
        <group group_id="P3">
          <title>Single Dose FMT Capsule DE</title>
          <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was completed with only 1 participant enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Low Dose FMT Capsule DE</title>
          <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Oral Capsule</title>
          <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
        </group>
        <group group_id="B3">
          <title>Single Dose FMT Capsule DE</title>
          <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Efficacy of Oral FMT on Composition and Function of the Gut Microbiota Compared to Placebo.</title>
        <description>Assess microbial composition of stool using 16s targeted sequencing and shotgun metagenomics</description>
        <time_frame>60 days</time_frame>
        <population>There are no results due to low enrollment (N=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose FMT Capsule DE</title>
            <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Oral Capsule</title>
            <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
          </group>
          <group group_id="O3">
            <title>Single Dose FMT Capsule DE</title>
            <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Efficacy of Oral FMT on Composition and Function of the Gut Microbiota Compared to Placebo.</title>
          <description>Assess microbial composition of stool using 16s targeted sequencing and shotgun metagenomics</description>
          <population>There are no results due to low enrollment (N=1).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Treatment-related Adverse Events in the Oral FMT Regimens Versus Placebo.</title>
        <description>Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0, including serious adverse events, will be assessed. We will also assess proportion of newly diagnosed infectious diseases, which are considered adverse events of special interest (AESI) after randomization.</description>
        <time_frame>60 days</time_frame>
        <population>There are no results due to low enrollment (N=1)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose FMT Capsule DE</title>
            <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose FMT Capsule DE</title>
            <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oral Capsule</title>
            <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Treatment-related Adverse Events in the Oral FMT Regimens Versus Placebo.</title>
          <description>Proportion of participants with treatment-related adverse events as assessed by CTCAE v4.0, including serious adverse events, will be assessed. We will also assess proportion of newly diagnosed infectious diseases, which are considered adverse events of special interest (AESI) after randomization.</description>
          <population>There are no results due to low enrollment (N=1)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Rate of Clostridium Difficile Infection (CDI) During Oral FMT Regimens Versus Placebo</title>
        <description>Collection of CDI infection rates from baseline to end of study and comparison between both oral FMT groups versus placebo.</description>
        <time_frame>60 days</time_frame>
        <population>There are no results due to low enrollment (N=1)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose FMT Capsule DE</title>
            <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose FMT Capsule DE</title>
            <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oral Capsule</title>
            <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Rate of Clostridium Difficile Infection (CDI) During Oral FMT Regimens Versus Placebo</title>
          <description>Collection of CDI infection rates from baseline to end of study and comparison between both oral FMT groups versus placebo.</description>
          <population>There are no results due to low enrollment (N=1)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Time to Clostridium Difficile Infection (CDI) and/or Colonization With C. Difficile.</title>
        <description>C. difficile colonization will be detected in stool samples submitted at baseline through end of study. If patients' become colonized, time from randomization to colonization is collected. Comparisons are made between the oral FMT groups and placebo.</description>
        <time_frame>60 days</time_frame>
        <population>There are no results due to low enrollment (N=1)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose FMT Capsule DE</title>
            <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
          </group>
          <group group_id="O2">
            <title>Single Dose FMT Capsule DE</title>
            <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Oral Capsule</title>
            <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Time to Clostridium Difficile Infection (CDI) and/or Colonization With C. Difficile.</title>
          <description>C. difficile colonization will be detected in stool samples submitted at baseline through end of study. If patients' become colonized, time from randomization to colonization is collected. Comparisons are made between the oral FMT groups and placebo.</description>
          <population>There are no results due to low enrollment (N=1)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Insufficient participant population, low enrollment</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose FMT Capsule DE</title>
          <description>FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic&#xD;
Low Dose FMT Capsule DE: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Oral Capsule</title>
          <description>Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic&#xD;
Placebo oral capsule: Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.</description>
        </group>
        <group group_id="E3">
          <title>Single Dose FMT Capsule DE</title>
          <description>FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.&#xD;
Single Dose FMT Capsule DE: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <description>Basal cell carcinoma, unrelated to study procedures, resolved without sequelae</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nasia Safdar</name_or_title>
      <organization>University of Wisconsin-Madison</organization>
      <phone>608-263-1545</phone>
      <email>ns2@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

